Merck-Pfizer Accelerate the development

Merck-Pfizer Accelerate the development of oral drugs to treat or stop COVID-19
Reuters reported that U.S鉊鉮葡鉊��鉊��鉊琊ocompanies Pfizer, Inc. and Merck & Co., Inc. announced Sept. 1 for trials of a new anti-COVID-19 drug, oral tablets. After the number of people infected with the coronavirus has experienced severe symptoms and required hospitalization in the United States, soaring.

Pfizer stated that The drug, code-named PF-07321332, is being tested in a trial of 1,140 adults, but asymptomatic. Patients hospitalized -07321332 with low-dose ritonavir is an existing drug For use as part of a combination drug to treat HIV-positive patients, Pfizer claims that PF-07321332 is designed to block the activity of the enzyme. One of the major viruses that cause COVID-19 needs to break its spread in the human body.

Pfizer said The company began trials of PF-07321332 in July. And preliminary results are expected around the fall later this year.

As Merck announced the new trial: Is it possible to study whether molnupiravir tablets Is it used to prevent COVID-19 infection among adults in the same household? When a family member is infected with the coronavirus, it is spread in the family by Merck and Ridgeback Biotheraputics. Development partners have started experimenting. Nupiravir in the last stage To see if it can prevent infections that don't require hospitalization. not aggravate Is it necessary to be hospitalized and die?

Molnupiravir is an antiviral drug designed to mislead the genetic material (RNA) of the virus to prevent it from multiplying. spread throughout the body

�嗉� ��澈閰訫�

�𧼮儔撘閧鍂

閮�鰐 TOP

�唳�銝𡃏楝

Rank: 1

2^#

martina28043�潸”�� 2021-9-8 16:49 | �芰�閰脖��

颲�此閬𤥁��𠰴予摰�

�𧼮儔撘閧鍂

TOP

餈𥪜��𡑒” �𧼮儔 �澆�